PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22418029-0	2012	Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging.	17-allylamino-demethoxygeldanamycin	91-126	heat shock transcription factor 1	Homo sapiens	28-47
26187127-4	2015	In this study, enhanced anti-proliferative activity of the Hsp90 inhibitors 17-allylamino-demethoxygeldanamycin (17-AAG) and AUY922 in androgen-sensitive and CRPC cells was achieved when the agents were used in combination with AR antagonists bicalutamide or enzalutamide.	17-allylamino-demethoxygeldanamycin	76-111	heat shock protein 90 alpha family class A member 1	Homo sapiens	59-64
26187127-4	2015	In this study, enhanced anti-proliferative activity of the Hsp90 inhibitors 17-allylamino-demethoxygeldanamycin (17-AAG) and AUY922 in androgen-sensitive and CRPC cells was achieved when the agents were used in combination with AR antagonists bicalutamide or enzalutamide.	17-allylamino-demethoxygeldanamycin	76-111	androgen receptor	Homo sapiens	228-230
31407066-0	2020	17-Allylamino-Demethoxygeldanamycin Ameliorate Microthrombosis Via HSP90/RIP3/NLRP3 Pathway After Subarachnoid Hemorrhage in Rats.	17-allylamino-demethoxygeldanamycin	0-35	myosin phosphatase Rho interacting protein	Rattus norvegicus	73-77
31407066-0	2020	17-Allylamino-Demethoxygeldanamycin Ameliorate Microthrombosis Via HSP90/RIP3/NLRP3 Pathway After Subarachnoid Hemorrhage in Rats.	17-allylamino-demethoxygeldanamycin	0-35	NLR family, pyrin domain containing 3	Rattus norvegicus	78-83
27659253-3	2017	Here, effects of the Hsp90 blocker 17-allylamino-demethoxygeldanamycin (17AAG) applied topically to the skin were determined in experimental inflammatory epidermolysis bullosa acquisita (EBA), an anti-type VII collagen autoantibody-induced blistering skin disease.	17-allylamino-demethoxygeldanamycin	35-70	heat shock protein 86, pseudogene 1	Mus musculus	21-26
28101166-4	2016	Thus, the present study assessed the clinical effectiveness of an anticancer drug and Hsp70 activator, 17-allylamino-demethoxygeldanamycin (17-AAG), to evaluate its potential as a treatment for patients with TBI.	17-allylamino-demethoxygeldanamycin	103-138	N-methylpurine DNA glycosylase	Homo sapiens	143-146
26364610-3	2016	Since the HSP90 inhibitor 17-allylamino-demethoxygeldanamycin (17AAG) is developed in clinics, we explored here its ability to control intestinal acute GvHD in vivo in two mouse GvHD models (C57BL/6 BALB/c and FVB/N Lgr5-eGFP), ex vivo in intestine organoids and in vitro in intestinal epithelial cultures.	17-allylamino-demethoxygeldanamycin	26-61	heat shock protein 86, pseudogene 1	Mus musculus	10-15
26364610-3	2016	Since the HSP90 inhibitor 17-allylamino-demethoxygeldanamycin (17AAG) is developed in clinics, we explored here its ability to control intestinal acute GvHD in vivo in two mouse GvHD models (C57BL/6 BALB/c and FVB/N Lgr5-eGFP), ex vivo in intestine organoids and in vitro in intestinal epithelial cultures.	17-allylamino-demethoxygeldanamycin	26-61	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	216-220
25858486-3	2015	Preclinical findings implicate that 17-allylamino-demethoxygeldanamycin (17-AAG), an anticancer drug in clinical, provide neuroprotection actions in a rat model of traumatic brain injury, and the beneficial effects of 17-AAG were specifically due to up-regulation of Hsp70.	17-allylamino-demethoxygeldanamycin	36-71	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	267-272
23379601-1	2013	The HSP90 (heat-shock protein 90) inhibitor 17-AAG (17-allylamino-demethoxygeldanamycin) increases osteoclast formation both in vitro and in vivo, an action that can enhance cancer invasion and growth in the bone microenvironment.	17-allylamino-demethoxygeldanamycin	52-87	heat shock protein, 2	Mus musculus	4-9
23379601-1	2013	The HSP90 (heat-shock protein 90) inhibitor 17-AAG (17-allylamino-demethoxygeldanamycin) increases osteoclast formation both in vitro and in vivo, an action that can enhance cancer invasion and growth in the bone microenvironment.	17-allylamino-demethoxygeldanamycin	52-87	heat shock protein, 2	Mus musculus	11-32
23379601-1	2013	The HSP90 (heat-shock protein 90) inhibitor 17-AAG (17-allylamino-demethoxygeldanamycin) increases osteoclast formation both in vitro and in vivo, an action that can enhance cancer invasion and growth in the bone microenvironment.	17-allylamino-demethoxygeldanamycin	52-87	N-methylpurine-DNA glycosylase	Mus musculus	47-50
22418029-3	2012	We demonstrate that an [124I]iodide-pQHNIG70 positron emission tomography (PET) reporter system that includes an inducible HSP70 promoter can be used to image and monitor the activation of the HSF1/HSP70 transcription factor in response to drug treatment (17-allylamino-demethoxygeldanamycin [17-AAG]).	17-allylamino-demethoxygeldanamycin	256-291	heat shock protein family A (Hsp70) member 4	Homo sapiens	123-128
22418029-3	2012	We demonstrate that an [124I]iodide-pQHNIG70 positron emission tomography (PET) reporter system that includes an inducible HSP70 promoter can be used to image and monitor the activation of the HSF1/HSP70 transcription factor in response to drug treatment (17-allylamino-demethoxygeldanamycin [17-AAG]).	17-allylamino-demethoxygeldanamycin	256-291	heat shock transcription factor 1	Homo sapiens	193-197
22418029-3	2012	We demonstrate that an [124I]iodide-pQHNIG70 positron emission tomography (PET) reporter system that includes an inducible HSP70 promoter can be used to image and monitor the activation of the HSF1/HSP70 transcription factor in response to drug treatment (17-allylamino-demethoxygeldanamycin [17-AAG]).	17-allylamino-demethoxygeldanamycin	256-291	heat shock protein family A (Hsp70) member 4	Homo sapiens	198-203
20138026-8	2010	We have used this strain to demonstrate that significant levels of resistance to the Hsp90 inhibitors radicicol and 17-allylamino-demethoxygeldanamycin (17-AAG) are generated as a result of the same single point mutation within the native Hsp90 of yeast (A107N), the human Hsp90alpha (A121N) and the human Hsp90beta (A116N).	17-allylamino-demethoxygeldanamycin	116-151	Hsp90 family chaperone HSP82	Saccharomyces cerevisiae S288C	85-90
20138026-8	2010	We have used this strain to demonstrate that significant levels of resistance to the Hsp90 inhibitors radicicol and 17-allylamino-demethoxygeldanamycin (17-AAG) are generated as a result of the same single point mutation within the native Hsp90 of yeast (A107N), the human Hsp90alpha (A121N) and the human Hsp90beta (A116N).	17-allylamino-demethoxygeldanamycin	116-151	Hsp90 family chaperone HSP82	Saccharomyces cerevisiae S288C	239-244
20138026-8	2010	We have used this strain to demonstrate that significant levels of resistance to the Hsp90 inhibitors radicicol and 17-allylamino-demethoxygeldanamycin (17-AAG) are generated as a result of the same single point mutation within the native Hsp90 of yeast (A107N), the human Hsp90alpha (A121N) and the human Hsp90beta (A116N).	17-allylamino-demethoxygeldanamycin	116-151	heat shock protein 90 alpha family class A member 1	Homo sapiens	273-283
20138026-8	2010	We have used this strain to demonstrate that significant levels of resistance to the Hsp90 inhibitors radicicol and 17-allylamino-demethoxygeldanamycin (17-AAG) are generated as a result of the same single point mutation within the native Hsp90 of yeast (A107N), the human Hsp90alpha (A121N) and the human Hsp90beta (A116N).	17-allylamino-demethoxygeldanamycin	116-151	heat shock protein 90 alpha family class B member 1	Homo sapiens	306-315
19809428-1	2009	BACKGROUND: We determined how CXC-chemokine signalling and necrosis factor-kappaB (NF-kappaB) activity affected heat-shock protein 90 (Hsp90) inhibitor (geldanamycin (GA) and 17-allylamino-demethoxygeldanamycin (17-AAG)) cytotoxicity in castrate-resistant prostate cancer (CRPC).	17-allylamino-demethoxygeldanamycin	175-210	heat shock protein 90 alpha family class A member 1	Homo sapiens	135-140
18794130-1	2008	Despite studies that show the antitumor activity of Hsp90 inhibitors, such as geldanamycin (GA) and its derivative 17-allylamino-demethoxygeldanamycin (17-AAG), recent reports indicate that these inhibitors lack significant single-agent clinical activity.	17-allylamino-demethoxygeldanamycin	115-150	heat shock protein 90 alpha family class A member 1	Homo sapiens	52-57
15150124-0	2004	Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.	17-allylamino-demethoxygeldanamycin	17-52	fms related receptor tyrosine kinase 3	Homo sapiens	166-171
17108135-1	2006	17-Allylamino-demethoxygeldanamycin (17-AAG), currently in phase I and II clinical trials as an anticancer agent, binds to the ATP pocket of heat shock protein (Hsp90).	17-allylamino-demethoxygeldanamycin	0-35	N-methylpurine DNA glycosylase	Homo sapiens	40-43
17108135-1	2006	17-Allylamino-demethoxygeldanamycin (17-AAG), currently in phase I and II clinical trials as an anticancer agent, binds to the ATP pocket of heat shock protein (Hsp90).	17-allylamino-demethoxygeldanamycin	0-35	heat shock protein 90 alpha family class A member 1	Homo sapiens	161-166
16267026-1	2005	We have examined the role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the bioreductive metabolism of 17-allylamino-demethoxygeldanamycin (17-AAG).	17-allylamino-demethoxygeldanamycin	103-138	NAD(P)H quinone dehydrogenase 1	Homo sapiens	29-61
16267026-1	2005	We have examined the role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the bioreductive metabolism of 17-allylamino-demethoxygeldanamycin (17-AAG).	17-allylamino-demethoxygeldanamycin	103-138	NAD(P)H quinone dehydrogenase 1	Homo sapiens	63-67
16267026-1	2005	We have examined the role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the bioreductive metabolism of 17-allylamino-demethoxygeldanamycin (17-AAG).	17-allylamino-demethoxygeldanamycin	103-138	N-methylpurine DNA glycosylase	Homo sapiens	143-146
34242681-5	2021	Using at specific blocker for HSP90 ATPase activity, 17-allylamino-demethoxygeldanamycin (17-AAG), we found that the HSP90 ATPase domain is indispensable for maintaining the interaction between HSP90 and Rab11b in osteoclasts.	17-allylamino-demethoxygeldanamycin	53-88	heat shock protein, 3	Mus musculus	30-35
34242681-5	2021	Using at specific blocker for HSP90 ATPase activity, 17-allylamino-demethoxygeldanamycin (17-AAG), we found that the HSP90 ATPase domain is indispensable for maintaining the interaction between HSP90 and Rab11b in osteoclasts.	17-allylamino-demethoxygeldanamycin	53-88	heat shock protein, 3	Mus musculus	117-122
34242681-5	2021	Using at specific blocker for HSP90 ATPase activity, 17-allylamino-demethoxygeldanamycin (17-AAG), we found that the HSP90 ATPase domain is indispensable for maintaining the interaction between HSP90 and Rab11b in osteoclasts.	17-allylamino-demethoxygeldanamycin	53-88	heat shock protein, 3	Mus musculus	194-199
34242681-5	2021	Using at specific blocker for HSP90 ATPase activity, 17-allylamino-demethoxygeldanamycin (17-AAG), we found that the HSP90 ATPase domain is indispensable for maintaining the interaction between HSP90 and Rab11b in osteoclasts.	17-allylamino-demethoxygeldanamycin	53-88	RAB11B, member RAS oncogene family	Mus musculus	204-210